Drug Supply Chain

340B Reform: Who Profits From Drug Discounts Now?

Huddle #Trends

FDA Peptide Policy Raises Safety Concerns for Doctors

PBM Reform 2026: What the New Rules Mean for Drug Prices and Your Patients

The FTC Just Settled With a PBM

What's Actually Changing in Drug Pricing?

Inside TrumpRx: GoodRx Coupons, Who Profits, and Real Drug Costs

Huddle #Trends

Pharma’s New DTC Playbook: TikTok, TrumpRx, and What It Means for Physicians

Amazon's Prescription Kiosks Will Succeed Where Others Failed

Pharmaceutical Wholesalers: The Middlemen Who Control 92% of U.S. Drug Distribution

The Middlemen: Pharmaceutical Wholesalers

Pharma’s Direct-to-Consumer Strategy: Telehealth Deals Explained

Amazon RxPass: Does a $5 Drug Subscription Improve Adherence?

Inefficiency Insights #67

Can Text Reminders Fix Medication Adherence? A New Study Says No—But AI Might

Inefficiency Insights #66

The 340B Drug Program: How Hospitals Profit While Patients Pay

Huddle #Trends

CMS Reveals 15 Drugs for Medicare Negotiation, Including Ozempic

Humira Biosimilars: Market Impact, Cost Savings, and Future Trends

Cost Plus Drugs Partnerships: Cutting Drug Costs for Health Systems

6 Practical Ways to Save on High U.S. Prescription Drug Costs

Inefficiency Insights #57

Curing Hepatitis C: The Netflix Model Explained

Why Are U.S. Drug Prices So High? Solutions for Lowering Costs

Huddle #Trends

CMS Negotiates Drug Prices: The Not-so-Clear Impact on Medicare Spending

A Comprehensive Analysis of Mark Cuban's Cost Plus Drugs Company

Huddle+ | Huddle #Trends

The Rise of Humira Biosimilars and the Battle for Market Share

The Inflation Reduction Act (2022)

Healthcare Concepts

High Drug Pricing in the U.S.

Healthcare Concepts

Generics vs. Brand-name vs. Biosimilars

Healthcare Concepts

Inflation Reduction Act

Healthcare Concepts